Approved indications: Veozah is approved to treat moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause in adults.

Off-label uses: As of now, it is primarily used for menopausal vasomotor symptoms; other potential uses (for example in related hormone-mediated symptoms) remain investigational and are not well established in routine practice.

Efficacy expectations: Many patients begin to notice fewer and less intense hot flashes within about 1–4 weeks, with continued improvement over several months; clinical trials showed significant reductions in the number and severity of hot flashes compared with placebo.

Comparison to similar drugs: Unlike hormone therapy (estrogen with or without progestin), Veozah is a nonhormonal NK3 receptor antagonist, offering an alternative for people who cannot or prefer not to use estrogen; its benefit is mainly on hot flashes, not on bone density, vaginal symptoms, or other menopause-related issues that hormone therapy may also address.

Typical dosing: The usual dose of Veozah for moderate to severe menopausal hot flashes is 45 mg taken by mouth once daily, at about the same time each day, with or without food, swallowing the tablet whole.

Special dosing instructions: Before starting, liver function tests are typically checked; use may be avoided or adjusted in people with certain liver problems or those taking strong inhibitors of specific liver enzymes (such as some CYP1A2 inhibitors), according to prescriber guidance.

Missed dose guidance: If a dose is missed and it is still the same day, take it as soon as remembered; if it is nearly time for the next dose, skip the missed dose and resume the regular schedule, without doubling doses.

Overdose: In case of suspected overdose, seek emergency medical care or contact a poison control center right away; treatment is supportive while monitoring for side effects, especially on the liver.

Common side effects: The most frequently reported effects include abdominal pain, diarrhea, insomnia, back pain, and hot flush or flushing; they are usually mild to moderate and often appear in the first weeks of treatment.

Serious or rare adverse effects: Veozah can affect liver function in some people; signs such as unusual fatigue, loss of appetite, right upper abdominal pain, dark urine, or yellowing of the skin or eyes require prompt medical attention and possible drug discontinuation.

Warnings and precautions: Veozah is not recommended in people with cirrhosis or significant liver impairment, or in those taking certain strong liver enzyme inhibitors; liver blood tests are typically checked before starting and periodically during treatment. Use in pregnancy is not expected to be relevant because it is for menopausal symptoms, but it is generally avoided in pregnancy and breastfeeding due to limited data. It is approved for adults only and not for children or adolescents.

Safety compared with other options: Because it is nonhormonal, Veozah avoids some hormone-related risks (such as those associated with systemic estrogen therapy), but it adds specific concerns about liver monitoring and interactions, so overall safety depends on an individual’s health profile.

Reporting side effects and safety updates: Patients and caregivers can report side effects to FDA MedWatch or to the manufacturer’s safety line, and updated safety information is provided through prescribing information, Medication Guides, and regulatory safety communications.

Drug and supplement interactions: Veozah is metabolized by liver enzymes, and strong inhibitors of CYP1A2 (such as certain antibiotics, antifungals, or fluvoxamine) can increase its levels and are generally avoided; patients should review all prescription medicines, over-the-counter drugs, and herbal supplements (including things like St. John’s wort or certain botanicals) with their clinician or pharmacist.

Food, alcohol, and other interactions: There are no strict food restrictions, and it may be taken with or without food; moderate alcohol use may be permitted but should be discussed with a clinician, especially in those with any liver concerns, because alcohol and Veozah both can stress the liver.

Precautions and contraindications: Veozah is not recommended for people with cirrhosis or severe liver impairment, and it should not be used with strong CYP1A2 inhibitors; caution is needed in people with a history of liver disease or abnormal liver tests, and in those taking multiple medicines that affect the liver.

Monitoring needs: Liver function tests are typically done before starting Veozah and repeated during treatment at intervals recommended by the prescriber (for example, at 3, 6, and 9 months, or as clinically indicated), and additional tests may be ordered if symptoms of liver problems appear.

Q: How long does it take for Veozah to start working on hot flashes?
A: Many people notice some improvement within 1 to 4 weeks, with continued benefit over several months as long as they keep taking it as prescribed.

Q: Is Veozah a hormone or a type of estrogen?
A: No, Veozah is a nonhormonal medicine called an NK3 receptor antagonist, so it works differently from estrogen-based hormone therapy.

Q: Do I need blood tests while taking Veozah?
A: Yes, your clinician will usually check liver blood tests before you start and repeat them during treatment to be sure your liver is tolerating the medicine.

Q: Can I take Veozah if I have liver problems?
A: Veozah is not recommended for people with cirrhosis or significant liver impairment, and it should be used very cautiously, if at all, in anyone with a history of liver disease, under close medical supervision.

Q: Can I stop Veozah suddenly if my symptoms get better?
A: It is not associated with withdrawal, but hot flashes may return if you stop; always talk with your clinician before changing how you take the medication.

Storage: Store Veozah tablets at room temperature (generally 68°F to 77°F or 20°C to 25°C), in the original container, tightly closed, and away from moisture and direct heat; keep out of reach of children and pets.

Disposal: Do not flush unused tablets down the toilet unless instructed; if possible, use a drug take-back program, or follow local guidance for mixing unused tablets with an undesirable substance (like coffee grounds or cat litter), sealing in a bag or container, and placing in household trash.